Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 150% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 06/16/2023 | 118.75% | Mizuho | → $3.5 | Reiterates | Neutral → Neutral |
| 05/30/2023 | 525% | Ladenburg Thalmann | $4 → $10 | Maintains | Buy |
| 05/09/2023 | 150% | Cantor Fitzgerald | $2 → $4 | Maintains | Overweight |
| 03/30/2023 | 118.75% | Mizuho | → $3.5 | Reiterates | → Neutral |
| 10/07/2022 | 25% | Ladenburg Thalmann | → $2 | Initiates Coverage On | → Buy |
| 12/03/2021 | 400% | Cantor Fitzgerald | $5 → $8 | Maintains | Overweight |
| 12/01/2021 | 400% | Jefferies | → $8 | Initiates Coverage On | → Buy |
| 08/03/2021 | 118.75% | Mizuho | $4 → $3.5 | Maintains | Neutral |
| 07/16/2021 | 275% | HC Wainwright & Co. | $9.5 → $6 | Maintains | Buy |
| 05/27/2021 | 525% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 03/26/2021 | 493.75% | HC Wainwright & Co. | $12 → $9.5 | Maintains | Buy |
| 02/10/2021 | 150% | Mizuho | $7 → $4 | Downgrades | Buy → Neutral |
| 10/06/2020 | 650% | HC Wainwright & Co. | $10 → $12 | Maintains | Buy |
| 03/13/2020 | 400% | Wedbush | $11 → $8 | Maintains | Outperform |
| 03/10/2020 | 525% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 09/12/2019 | 337.5% | Mizuho | → $7 | Initiates Coverage On | → Buy |
| 05/29/2019 | 275% | Roth Capital | → $6 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/07/2023 | 150% | 康托·菲茨杰拉德 | →$4 | 重申 | 超重→超重 |
| 06/16/2023 | 118.75% | 瑞穗 | →$3.5 | 重申 | 中性→中性 |
| 2023年05月30日 | 525% | 拉登堡·塔尔曼 | $4→$10 | 维护 | 买 |
| 05/09/2023 | 150% | 康托·菲茨杰拉德 | $2→$4 | 维护 | 超重 |
| 03/30/2023 | 118.75% | 瑞穗 | →$3.5 | 重申 | →中性 |
| 10/07/2022 | 25% | 拉登堡·塔尔曼 | →$2 | 开始承保 | →购买 |
| 12/03/2021 | 400% | 康托·菲茨杰拉德 | $5→$8 | 维护 | 超重 |
| 12/01/2021 | 400% | 杰富瑞 | →$8 | 开始承保 | →购买 |
| 08/03/2021 | 118.75% | 瑞穗 | $4→$3.5 | 维护 | 中性 |
| 07/16/2021 | 275% | HC Wainwright公司 | $9.5→$6 | 维护 | 买 |
| 2021/05/27 | 525% | 康托·菲茨杰拉德 | →$10 | 开始承保 | →超重 |
| 03/26/2021 | 493.75% | HC Wainwright公司 | $12→$9.5 | 维护 | 买 |
| 02/10/2021 | 150% | 瑞穗 | $7→$4 | 评级下调 | 购买→中性 |
| 10/06/2020 | 650% | HC Wainwright公司 | $10→$12 | 维护 | 买 |
| 03/13/2020 | 400% | 韦德布什 | $11→$8 | 维护 | 跑赢大盘 |
| 03/10/2020 | 525% | HC Wainwright公司 | →$10 | 开始承保 | →购买 |
| 2019/12/09 | 337.5% | 瑞穗 | →$7 | 开始承保 | →购买 |
| 2019年05月29日 | 275% | 罗斯资本 | →$6 | 开始承保 | →购买 |
What is the target price for Corvus Pharma (CRVS)?
Corvus Pharma(CRVS)的目标价是多少？
The latest price target for Corvus Pharma (NASDAQ: CRVS) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $4.00 expecting CRVS to rise to within 12 months (a possible 150.00% upside). 6 analyst firms have reported ratings in the last year.
康托·菲茨杰拉德于2023年9月7日报道了Corvus Pharma(纳斯达克：CRVS)的最新目标价。这家分析公司将目标价定为4美元，预计CRVS将在12个月内升至(可能上涨150.00%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Corvus Pharma (CRVS)?
Corvus Pharma(CRVS)的最新分析师评级是多少？
The latest analyst rating for Corvus Pharma (NASDAQ: CRVS) was provided by Cantor Fitzgerald, and Corvus Pharma reiterated their overweight rating.
纳斯达克(Sequoia Capital：CRVS)的最新分析师评级由康托·菲茨杰拉德提供，Corvus Pharma重申其增持评级。
When is the next analyst rating going to be posted or updated for Corvus Pharma (CRVS)?
Corvus Pharma(CRVS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Corvus Pharma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Corvus Pharma的上一次评级是在2023年9月7日提交的，所以你应该预计下一次评级将在2024年9月7日左右的某个时候提供。
Is the Analyst Rating Corvus Pharma (CRVS) correct?
分析师对Corvus Pharma(CRVS)的评级正确吗？
While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a reiterated with a price target of $0.00 to $4.00. The current price Corvus Pharma (CRVS) is trading at is $1.60, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Corvus Pharma(CRVS)评级被重申，目标价在0.00美元至4.00美元之间。Corvus Pharma(CRVS)目前的交易价格为1.60美元，在分析师的预测范围内。